September 25, 2012
AstraZeneca Pharmaceuticals LP on Tuesday agreed to pay $11 million to settle claims by a proposed class of indirect purchasers of hypertension drug Toprol-XL that the drugmaker used sham patent litigation to prolong a monopoly on the drug by delaying generic versions.
May 31, 2012
AstraZeneca Pharmaceuticals LP reached an agreement Wednesday to resolve claims brought in Delaware by a putative class of indirect purchasers of Toprol-XL who allege the pharmaceutical giant used sham patent litigation to delay generic competition for the hypertension drug.